Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
Not provided
Not provided
Not provided
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Methylphenidate first | Experimental | Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week. |
|
| Placebo first | Placebo Comparator | Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Methylphenidate | Drug | single dose of 10 mg or 15 mg |
| |
| Measure | Description | Time Frame |
|---|---|---|
| BOLD signal during response inhibition | BOLD signal (brain activity during fMRI, arbitrary units) in the anterior cingulate cortex during response inhibition. | Approximately 90 minutes after dose |
| Glutamate level in the anterior cingulate cortex | Glutamate level (measured by MRS, institutional units) in the anterior cingulate cortex. | Approximately 2 hours after dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kristin L Bigos, PhD | Contact | 410-614-0453 | kbigos1@jhu.edu | |
| Robyn Wiseman, BS | Contact | 304-551-3309 | rwisema5@jhmi.edu |
| Name | Affiliation | Role |
|---|---|---|
| Kristin L Bigos, PhD | Johns Hopkins School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins School of Medicine | Recruiting | Baltimore | Maryland | 21205 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008774 | Methylphenidate |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
This is a double-blind cross over of a single dose of methylphenidate (10mg or 15mg) and matching placebo.
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Matching placebo |
|
| D010880 |
| Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |